Role of positron emission tomography in the assessment of disease burden and risk of relapse in patients affected by giant cell arteritis
暂无分享,去创建一个
F. Orsini | M. Pirisi | L. Castello | G. Avanzi | P. Sainaghi | F. Gavelli | G. Sacchetti | A. Croce | D. Sola | M. Bellan | R. Pedrazzoli | E. Zecca | E. Puta | D. Soddu | Alessandro Croce
[1] I. Durieu,et al. Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta‐Analysis , 2020, Arthritis care & research.
[2] T. Takeuchi,et al. Body mass index associates with disease relapse in patients with giant cell arteritis , 2019, International journal of rheumatic diseases.
[3] D. Bailey,et al. Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double‐Blind, Cross‐Sectional Study , 2019, Arthritis & rheumatology.
[4] F. Martínez-Valle,et al. Risk of ischaemic events at giant cell arteritis diagnosis according to PET/CT findings , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[5] D. Mariano-Goulart,et al. Diagnostic performance of 18F-FDG PET-CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy , 2019, Annals of Nuclear Medicine.
[6] A. Aouba,et al. Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis , 2019, The Journal of Rheumatology.
[7] P. Giorgi Rossi,et al. Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study , 2018, Rheumatology.
[8] P. Bartenstein,et al. Diagnostic accuracy of positron emission tomography for assessment of disease activity in large vessel vasculitis , 2018, International journal of rheumatic diseases.
[9] J. Braun,et al. The role of 18F-FDG positron emission tomography for the diagnosis of vasculitides. , 2018, Clinical and experimental rheumatology.
[10] C. Baldini,et al. One year in review 2018: systemic vasculitis. , 2018, Clinical and experimental rheumatology.
[11] Eric L Matteson,et al. Large-vessel giant cell arteritis: diagnosis, monitoring and management , 2018, Rheumatology.
[12] A. Iagnocco,et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice , 2018, Annals of the rheumatic diseases.
[13] M. Aschwanden,et al. [18F]FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis—lessons from a vasculitis clinic , 2017, European heart journal cardiovascular Imaging.
[14] A. Aouba,et al. Giant-cell arteritis without cranial manifestations , 2016, Medicine.
[15] L. Cimino,et al. Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy , 2016, Medicine.
[16] E. Matteson,et al. Large-vessel giant cell arteritis: a cohort study. , 2015, Rheumatology.
[17] T. Kano,et al. Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT , 2014, Rheumatology International.
[18] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.
[19] L. Mortelmans,et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. , 2006, Arthritis and rheumatism.
[20] F. Strutz,et al. Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[21] A. Stanson,et al. Disease pattern in cranial and large-vessel giant cell arteritis. , 1999, Arthritis and rheumatism.
[22] Bouallègue,et al. Diagnostic performance of 18 F ‐ FDG PET ‐ CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy , 2019 .
[23] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.